We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pediatric Cancer Advisory Panel Recommends Moving Away From Single-Agent Studies
FDA Pediatric Cancer Advisory Panel Recommends Moving Away From Single-Agent Studies
An FDA pediatric cancer advisory panel called on multiple sponsors to continue refining their cancer drugs to adapt them for safe and effective use in pediatric populations.
